Related Experiment Video
Updated: Feb 20, 2026
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Erratum to: Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of
Insights
This erratum corrects detailed summary tables for circulating tumor markers clinical use guidelines. These tables provide evidence-based recommendations for healthcare providers and policymakers.
Area of Science:
- Biomarkers and Clinical Diagnostics
- Oncology
- Evidence-Based Medicine
Background:
- Clinical practice guidelines for circulating tumor markers are essential for appropriate use.
- Previous publications (Parts 1-3) provided comparative summaries of these recommendations.
- Detailed summary tables were included to support healthcare professionals.
Purpose of the Study:
- To report an amendment to the detailed summary tables previously published.
- To provide the correct definition and intended audience for these detailed summary tables.
- To ensure accurate and useful supplementary information for clinical decision-making.
Main Methods:
- Review and amendment of detailed summary tables across three parts of a guideline series.
- Clarification of the definition of detailed summary tables.
- Identification of target audiences for the detailed summary tables.
Main Results:
- An amendment to the detailed summary tables has been issued.
- Detailed summary tables are defined as comprehensive resources for each tumor type.
- These tables consolidate recommendations and supplementary data from various guidance documents.
Conclusions:
- The corrected detailed summary tables offer valuable, evidence-based information.
- The tables are designed for healthcare providers, policymakers, and educators.
- Accurate supplementary information enhances the appropriate clinical application of circulating tumor markers.
Abstract:
Erratum To: Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 1) Gion M, Trevisiol C, Rutjes AW, Rainato G, Fabricio AS. Int J Biol Markers. 2016 Dec 23;31(4):e332-e367. doi: 10.5301/jbm.5000251. Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 2).Gion M, Trevisiol C, Rutjes AWS, Rainato G, Fabricio ASC. Int J Biol Markers. 2017 Mar 2;32(1):e1-e52. doi: 10.5301/ijbm.5000259. Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 3).Gion M, Trevisiol C, Rutjes AWS, Rainato G, Fabricio ASC. Int J Biol Markers. 2017 May 4;32(2):e147-e181. doi: 10.5301/ijbm.5000272. We report an amendment in the Detailed summary tables pages of the three parts of the guidelines above. The correct definition of detailed summary tables is reported below. Definition and target audience Detailed summary tables are tables prepared for every tumor type which report recommendations and supplementary information from different guidance documents with enough details to be useful for health care providers, policy makers (for potential adaptation to specific settings) and staff developing educational material informed by available evidence.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...